Oncology drugs provided the clearest examples, with UGT1A1 variation predicting irinotecan toxicity and dihydropyrimidine dehydrogenase (DPYD) deficiency influencing fluoropyrimidine intolerance. This evidence concerns the gene UGT1A1 and hyperinsulinemic hypoglycemia, familial, 4.